NEW YORK, Oct. 3, 2022 /PRNewswire/ -- The "Anti-Thrombin III Testing Market by End-user (Hospitals, Laboratories, and Academic and research institutes) and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. North America will account for 38% of the market's growth during the forecast period. This growth is attributed to factors such as the growing adoption of anti-thrombin III testing for blood disorders in hospitals and laboratories. Moreover, market growth in this region will be faster than the growth of the market in other regions. The US and Canada are the key countries for the anti-thrombin III testing market in North America.
The potential growth difference for the anti-thrombin III testing market size between 2021 and 2026 is USD 161.48 million. To get the exact CAGR and the Y-O-Y growth rate, Request a FREE PDF Sample Report
Key Market Dynamics
Market Driver: The existence of tests for patients with anti-thrombin deficiency is driving the growth of the market. The testing comprises various related tests, such as prothrombin time (PT) test, activated partial thromboplastin time (aPTT) test, and thrombin time (TT) test, which help detect blood clots. The presence of such tests will fuel the demand for anti-thrombin III testing products during the forecast period.
Market Challenge: The lack of clinically available protocols to treat anti-thrombin deficiency is challenging the growth of the market. There is a lack of clinically available protocols to treat anti-thrombin deficiency, which may hinder the demand for anti-thrombin kits and reagents. Moreover, pregnant women with anti-thrombin deficiency are at a particularly high risk of developing clots during pregnancy or after delivery.
Technavio has identified key trends, drivers, and challenges in the market, which will help vendors improve their strategies to stay ahead of their competitors. View our FREE PDF Sample Report
By end-user, the hospital segment will be the largest contributor to market growth during the forecast period. Hospitals use anti-thrombin III testing products such as reagents, assay kits, and systems to conduct diagnostic tests. The sales of these products are expected to increase in hospitals owing to the rise in patient admissions for surgeries and diagnoses. Many hospitals have their own laboratories to perform diagnostic tests and detect blood disorders. Moreover, organizations such as the Centers for Disease Control and Prevention (CDC) are taking initiatives such as the introduction of anti-thrombin III testing toolkits. This will increase the need for such products in hospitals.
View our FREE PDF Sample Report for additional insights into the contribution of all the segments and regional opportunities in the report
Some Companies Mentioned
Beckman Coulter Inc.
Becton Dickinson and Co.
Bio Rad Laboratories Inc.
Biron Health Group Inc.
F. Hoffmann La Roche Ltd.
Meridian Bioscience Inc.
Oy Medix Biochemica Ab
Randox Laboratories Ltd.
Scripps Laboratories Inc.
Sekisui Diagnostics LLC
Thermo Fisher Scientific Inc.
Transasia Bio Medicals Ltd.
Want your report customized? Speak to an analyst and personalize your report according to your needs
Point of Care Diagnostics Market by Product, End-user, and Geography - Forecast and Analysis 2022-2026: The point of care diagnostics market share is expected to increase by USD 13.09 billion from 2021 to 2026.
Molecular Microplate Readers and Washers Market by Product, End-user, and Geography - Forecast and Analysis 2022-2026: The molecular microplate readers and washers market share is expected to increase by USD 312.89 million from 2021 to 2026.
Anti-Thrombin III Testing Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 7.73%
Market growth 2022-2026
USD 161.48 million
YoY growth (%)
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 38%
Key consumer countries
US, Canada, Germany, UK, and China
Leading companies, competitive strategies, consumer engagement scope
Abbott Laboratories, Beckman Coulter Inc., Becton Dickinson and Co., Bio Rad Laboratories Inc., Biron Health Group Inc., Danaher Corp., F. Hoffmann La Roche Ltd., Grifols SA, Invitae Corp., Merck KGaA, Meridian Bioscience Inc., Oy Medix Biochemica Ab, Randox Laboratories Ltd., Scripps Laboratories Inc., Sekisui Diagnostics LLC, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., Transasia Bio Medicals Ltd., and Werfenlife SA
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Browse Health Care Market Reports
Key Topics Covered
1 Executive Summary
1.1 Market overview
2 Market Landscape
2.1 Market ecosystem
3 Market Sizing
3.1 Market definition
3.2 Market segment analysis
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
4 Five Forces Analysis
4.1 Five forces summary
4.2 Bargaining power of buyers
4.3 Bargaining power of suppliers
4.4 Threat of new entrants
4.5 Threat of substitutes
4.6 Threat of rivalry
4.7 Market condition
5 Market Segmentation by End-user
5.1 Market segments
5.2 Comparison by End-user
5.3 Hospitals - Market size and forecast 2021-2026
5.4 Laboratories - Market size and forecast 2021-2026
5.5 Academic and research institutes - Market size and forecast 2021-2026
5.6 Market opportunity by End-user
6 Customer Landscape
6.1 Customer landscape overview
7 Geographic Landscape
7.1 Geographic segmentation
7.2 Geographic comparison
7.3 North America - Market size and forecast 2021-2026
7.4 Europe - Market size and forecast 2021-2026
7.5 Asia - Market size and forecast 2021-2026
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
7.7 US - Market size and forecast 2021-2026
7.8 Germany - Market size and forecast 2021-2026
7.9 China - Market size and forecast 2021-2026
7.10 UK - Market size and forecast 2021-2026
7.11 Canada - Market size and forecast 2021-2026
7.12 Market opportunity by geography
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
8.4 Market trends
9 Vendor Landscape
9.2 Vendor landscape
9.3 Landscape disruption
9.4 Industry risks
10 Vendor Analysis
10.1 Vendors covered
10.2 Market positioning of vendors
10.3 Abbott Laboratories
10.4 Becton Dickinson and Co.
10.5 Bio Rad Laboratories Inc.
10.6 Danaher Corp.
10.7 F. Hoffmann La Roche Ltd.
10.8 Grifols SA
10.9 Siemens AG
10.10 Sysmex Corp.
10.11 Thermo Fisher Scientific Inc.
10.12 Transasia Bio Medicals Ltd.
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
11.3 Currency conversion rates for US$
11.4 Research methodology
11.5 List of abbreviations
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View original content to download multimedia:https://www.prnewswire.com/news-releases/anti-thrombin-iii-testing-market-size-to-grow-by-usd-161-48-million-majority-of-market-growth-to-originate-from-north-america---technavio-301637737.html